Published in Breast Cancer (Auckl) on September 27, 2015
Aberrant Promoter Methylation of the Tumour Suppressor RASSF10 and Its Growth Inhibitory Function in Breast Cancer. Cancers (Basel) (2016) 0.77
The Necrosis-Avid Small Molecule HQ4-DTPA as a Multimodal Imaging Agent for Monitoring Radiation Therapy-Induced Tumor Cell Death. Front Oncol (2016) 0.75
Erianin inhibits the proliferation of T47D cells by inhibiting cell cycles, inducing apoptosis and suppressing migration. Am J Transl Res (2016) 0.75
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer (2005) 13.49
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol (2013) 9.68
Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev (2004) 9.28
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet (2011) 8.24
The dawning era of polymer therapeutics. Nat Rev Drug Discov (2003) 7.86
Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev (2002) 7.05
Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer (2006) 5.75
Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res (2008) 5.67
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol (2011) 5.63
Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine (2008) 4.59
PLGA-based nanoparticles: an overview of biomedical applications. J Control Release (2012) 4.39
Comparative effectiveness of digital versus film-screen mammography in community practice in the United States: a cohort study. Ann Intern Med (2011) 4.31
Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces (2009) 4.06
Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res (2003) 3.89
Applications of carbon nanotubes in drug delivery. Curr Opin Chem Biol (2005) 3.77
PEG-modified gold nanorods with a stealth character for in vivo applications. J Control Release (2006) 3.74
Delivery materials for siRNA therapeutics. Nat Mater (2013) 3.70
Nanomaterials and nanoparticles: sources and toxicity. Biointerphases (2007) 3.64
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol (2009) 3.63
Breast cancer in men. Ann Intern Med (2002) 3.39
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 3.25
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release (2010) 3.06
Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev (2000) 2.85
Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes (2009) 2.78
Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol (2008) 2.73
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 2.66
Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med (2009) 2.39
Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release (2011) 2.37
Understanding breast cancer risk -- where do we stand in 2005? J Cell Mol Med (2005) 2.21
Design of liposomes for enhanced local release of drugs by hyperthermia. Science (1978) 2.17
Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. J Clin Oncol (2015) 2.17
Amphiphilic block copolymers for drug delivery. J Pharm Sci (2003) 1.86
Tumour-targeted nanomedicines: principles and practice. Br J Cancer (2008) 1.81
A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res (2010) 1.72
Basic science of HER-2/neu: a review. Semin Oncol (1999) 1.70
Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology (2008) 1.65
Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer (2006) 1.59
Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci (1995) 1.58
Targeted delivery of amphotericin B to cells by using functionalized carbon nanotubes. Angew Chem Int Ed Engl (2005) 1.55
A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J Nucl Med (2009) 1.51
Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. Cancer Res (1990) 1.49
Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials (2009) 1.48
Breast biopsy in women 30 years old or less. Am J Surg (1993) 1.45
Male breast cancer. Cancer Treat Rev (2010) 1.35
The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity. Nanomedicine (2009) 1.32
Histological, molecular and functional subtypes of breast cancers. Cancer Biol Ther (2010) 1.30
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs (2014) 1.26
Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma. Drugs (2011) 1.25
Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol (2010) 1.24
DNA methylation profiling in breast cancer discordant identical twins identifies DOK7 as novel epigenetic biomarker. Carcinogenesis (2012) 1.22
Leptin-STAT3-G9a Signaling Promotes Obesity-Mediated Breast Cancer Progression. Cancer Res (2015) 1.21
Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases. Am J Clin Pathol (2000) 1.15
Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc Jpn Acad Ser B Phys Biol Sci (2012) 1.14
A hypothesis of the origin of human breast cancer from the terminal ductal lobular unit. Pathol Res Pract (1980) 1.13
Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Br J Cancer (2012) 1.12
Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. J Transl Med (2012) 1.10
Cardiotoxicity profile of trastuzumab. Drug Saf (2008) 1.09
Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics. Breast Cancer Res (2015) 1.08
Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin Oncol (2004) 1.08
Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J Drug Deliv (2013) 1.06
AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery. Biotechnol Bioeng (2012) 1.06
Palbociclib: an evidence-based review of its potential in the treatment of breast cancer. Breast Cancer (Dove Med Press) (2014) 1.05
Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary. Expert Opin Pharmacother (2006) 1.04
Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease. Curr Opin Obstet Gynecol (2011) 1.03
Magnetic resonance imaging in breast cancer. Eur J Surg Oncol (2006) 1.02
Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions. Breast Cancer (Auckl) (2013) 1.02
Molecular breast imaging. Expert Rev Anticancer Ther (2009) 1.01
Development of viral nanoparticles for efficient intracellular delivery. Nanoscale (2012) 0.99
Bioconjugation of calcium phosphosilicate composite nanoparticles for selective targeting of human breast and pancreatic cancers in vivo. ACS Nano (2010) 0.99
Bisphosphonates for breast cancer. Cochrane Database Syst Rev (2002) 0.98
Bioresponsive matrices in drug delivery. J Biol Eng (2010) 0.98
A 2D mechanistic model of breast ductal carcinoma in situ (DCIS) morphology and progression. J Theor Biol (2009) 0.96
Recent advances in breast MRI and MRS. NMR Biomed (2009) 0.96
Novel nanomedicine-based MRI contrast agents for gynecological malignancies. Adv Drug Deliv Rev (2009) 0.95
Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS. Clin Oncol (R Coll Radiol) (1994) 0.95
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. Oncologist (2014) 0.95
Targeting breast cancer with CDK inhibitors. Curr Oncol Rep (2015) 0.94
mTOR inhibitors in the treatment of breast cancer. Oncology (Williston Park) (2013) 0.94
Hormonal therapies in young breast cancer patients: when, what and for how long? J Thorac Dis (2013) 0.94
Tumor microvascular characterization using ultrasmall superparamagnetic iron oxide particles (USPIO) in an experimental breast cancer model. J Magn Reson Imaging (2001) 0.94
Design Strategies for Fluorescent Biodegradable Polymeric Biomaterials. J Mater Chem B Mater Biol Med (2013) 0.94
Particle shape: a new design parameter for passive targeting in splenotropic drug delivery. J Pharm Sci (2010) 0.93
Diagnosis and management of benign, atypical, and indeterminate breast lesions detected on core needle biopsy. Mayo Clin Proc (2014) 0.93
Breast cancer screening and biomarkers. Methods Mol Biol (2009) 0.92
Nanoshells for photothermal cancer therapy. Methods Mol Biol (2010) 0.91
Breast cancer management: past, present and evolving. Indian J Cancer (2012) 0.90
Doxil in breast cancer. J Clin Oncol (1998) 0.90
Optical and magnetic resonance imaging of cell death and platelet activation using annexin a5-functionalized quantum dots. Nano Lett (2007) 0.90
Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information. Clin Med Insights Oncol (2014) 0.89
Inorganic nanoparticles for predictive oncology of breast cancer. Nanomedicine (Lond) (2009) 0.89
In vitro antitumor activity of methotrexate via pH-sensitive chitosan nanoparticles. Biomaterials (2013) 0.89
Ca2+-binding protein S100A11: a novel diagnostic marker for breast carcinoma. Oncol Rep (2010) 0.89
Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials. Breast (2012) 0.88